An international randomized cross-over bio-equivalence study of oral paclitaxel 1 HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours

C G C A Jackson, S Deva, K Bayston, B Mclaren, P Barlow, Noelyn Anne Hung, K Clarke, Eva Segelov, T.-Y Chao, M.-S Dai, H. -T Yen, D Cutler, J Zhi, W.-K Chan, M.-F R Kwan, C - T Hung

Research output: Contribution to journalMeeting AbstractOtherpeer-review

Original languageEnglish
Number of pages2
JournalAnnals of Oncology
Volume30
Issue numberSupp 5
DOIs
Publication statusPublished - Oct 2019
EventESMO Congress (ESMO) 2019 - Barcelona, Spain
Duration: 27 Sep 20191 Oct 2019

Cite this

Jackson, C. G. C. A., Deva, S., Bayston, K., Mclaren, B., Barlow, P., Hung, N. A., Clarke, K., Segelov, E., Chao, T. -Y., Dai, M. -S., Yen, H. -T., Cutler, D., Zhi, J., Chan, W. -K., Kwan, M. -F. R., & Hung, C. . T. (2019). An international randomized cross-over bio-equivalence study of oral paclitaxel 1 HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours. Annals of Oncology, 30(Supp 5). https://doi.org/10.1093/annonc/mdz244.039